Most Read Articles
Pearl Toh, 4 days ago
Adding dapagliflozin to standard of care (SOC) significantly reduces the risk of worsening kidney function, death due to kidney or cardiovascular (CV) disease, and all-cause mortality compared with SOC alone in patients with chronic kidney disease (CKD), regardless of whether they have type 2 diabetes (T2D), reveals the DAPA-CKD* trial — showing dapagliflozin charting new territories from diabetes to the renal realm.
Roshini Claire Anthony, 4 days ago

In patients with chronic heart failure with reduced ejection fraction (HFrEF), empagliflozin reduced the risk of cardiovascular (CV) death or heart failure hospitalization (HHF) and decline in estimated glomerular filtration rate (eGFR), results of the EMPEROR-Reduced* trial showed.

Vitamin D, oestrogen protect against metabolic syndrome after menopause

17 Jul 2019

Deficiencies in vitamin D and oestrogen contribute to additive increases in the risk of metabolic syndrome in postmenopausal women, a recent study has found.

The cross-sectional study included 616 postmenopausal women aged 49-86 years. None of them were taking oestrogen and vitamin D/calcium supplements. Researchers measured serum oestradiol (E2) and 25(OH)D for each participant in relation to the risk of metabolic syndrome, which was defined according to the 2006 International Diabetes Federation standard.

Results showed a positive correlation between 25(OH)D and E2. Higher 25(OH)D concentration was associated with a favourable lipid profile, blood pressure and glucose level. On the other hand, higher E2 concentration was associated with low levels of cholesterol, triglycerides and blood pressure.

Women with vitamin D deficiency were twice as likely as those with sufficient vitamin D levels to have metabolic syndrome (odds ratio [OR], 2.19, 95 percent CI, 1.19–4.01; p-trend=0.009). This association remained significant despite controlling for E2 levels.

On further analysis stratifying by vitamin D status, low E2 concentration augmented the risk of metabolic syndrome in women with vitamin D deficiency (lowest vs highest tertile of E2: OR, 3.49, 1.45–8.05).

The present data suggest that vitamin D and E2 deficiencies exert a potential synergistic effect on the risk of metabolic syndrome in postmenopausal women, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 4 days ago
Adding dapagliflozin to standard of care (SOC) significantly reduces the risk of worsening kidney function, death due to kidney or cardiovascular (CV) disease, and all-cause mortality compared with SOC alone in patients with chronic kidney disease (CKD), regardless of whether they have type 2 diabetes (T2D), reveals the DAPA-CKD* trial — showing dapagliflozin charting new territories from diabetes to the renal realm.
Roshini Claire Anthony, 4 days ago

In patients with chronic heart failure with reduced ejection fraction (HFrEF), empagliflozin reduced the risk of cardiovascular (CV) death or heart failure hospitalization (HHF) and decline in estimated glomerular filtration rate (eGFR), results of the EMPEROR-Reduced* trial showed.